Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer

Showing 15 posts of 150 posts found.

Syrum image

Boehringer’s Syrum Facebook game launch date released

August 22, 2012
Medical Communications Boehringer, Facebook, Syrum

Boehringer Ingelheim has announced the launch date of its social media game Syrum. John Pugh, Boehringer’s director of digital communications …

News

Boehringer posts strong financials

August 16, 2012
Sales and Marketing AMNOG, Boehringer, COPD, Spiriva

Boehringer Ingelheim has seen steady growth in the first half of 2012, but warns that the next six months may …

News

Boehringer collaborates for online ‘beyond pill’ plan

July 11, 2012
Medical Communications Boehringer, diabetes, digital, healthrageous

Boehringer Ingelheim is collaborating with US digital health specialist Healthrageous on a scheme to help type II diabetes sufferers manage …

News
Xarelto image

Priority review for Xarelto’s new indications

July 10, 2012
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Eliquis, FDA, Janssen, Pradaxa, Xarelto

Xarelto is to be given a FDA fast-track review for a range of anti-blood clotting uses. Xarelto (rivaroxaban) gained its …

News

Boehringer collaborates with Havard

July 9, 2012
Research and Development, Sales and Marketing Boehringer, Havard, oncology, research deal

Boehringer Ingelheim has established a translational research collaboration with the presidents and fellows of Harvard College. The aim of the …

News
kct_2011_bournemouth_and_poole

Boehringer seeks NHS partners for COPD campaign

June 1, 2012
Medical Communications, Sales and Marketing Boehringer, COPD, disease awareness campaign

Boehringer is seeking NHS partners for its COPD campaign: ‘Know it. Check it. Treat it.’  The campaign aims to raise …

News
Pradaxa image

European OK for Pradaxa, but more details required

May 29, 2012
Research and Development, Sales and Marketing Boehringer, CHMP, EMA, Europe, Pradaxa

The European Medicines Agency says that Boehringher’s Pradaxa can stay on the market, but will need more safety information.  The …

News

Boehringer’s COPD drug passes hurdle

May 23, 2012
Research and Development, Sales and Marketing Boehringer, COPD, Daxas, Relovair, Spiriva, olodaterol

Boehringer Ingelheim’s once-daily bronchodilator olodaterol has improved lung function versus placebo in a Phase II trial.  The manufacturer wants the …

News

Gamification and online communities – what can pharma do?

May 10, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Facebook, Gamification, Syrum, digital marketing

Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This new …

Feature

Boehringer expands manufacturing in China

December 15, 2011
Manufacturing and Production Boehringer, China, manufacturing

Boehringer Ingelheim plans to invest €50 million in its manufacturing plant in Shanghai as part of a drive to increase …

News
Boehringer

Boehringer signs away HIV rights to focus on hep C

October 7, 2011
Research and Development Boehringer, Gilead, HIV, hepatitis C

Boehringer Ingelheim has signed a deal giving Gilead Sciences exclusive worldwide rights to a major part of its HIV portfolio. …

News
Boehringer Ingelheim

Boehringer to create biosimilars division

September 27, 2011
Research and Development Boehringer, biosimilars

Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that …

News

Boehringer censured over Pradaxa marketing

September 23, 2011
Medical Communications ABPI Code of Practice, Boehringer

Boehringer Ingelheim has been heavily censured by the body which enforces the ABPI’s Code of Practice for the content of …

News
Boehringer Ingelheim

Boehringer’s Trajenta launched in the UK

September 20, 2011
Sales and Marketing Boehringer, Trajenta, diabetes

Boehringer Ingelheim has launched its new diabetes drug Trajenta in the UK, with a price tag to match its rival …

News

Boehringer expands afatinib breast cancer trials

August 31, 2011
Research and Development Boehringer, afatinib

Boehringer Ingelheim has begun two new phase II trials of its investigational cancer drug afatinib. The studies will cover afatinib’s …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026